Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-09-15), Medivir AB's 3-1 Month Momentum % is N/A%.
The industry rank for Medivir AB's 3-1 Month Momentum % or its related term are showing as below:
CHIX:MVIRs's 3-1 Month Momentum % is not ranked *
in the Biotechnology industry.
Industry Median: 1.49 * Ranked among companies with meaningful 3-1 Month Momentum % only.
Medivir AB (CHIX:MVIRs) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Medivir AB 3-1 Month Momentum % Related Terms
CHIX:MVIRS vs VRTX, REGN, MRNA: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Medivir AB's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medivir AB 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Medivir AB's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Medivir AB's 3-1 Month Momentum % falls into.
Medivir AB (CHIX:MVIRs) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medivir AB (CHIX:MVIRS) has a 3-1 Month Momentum % of N/A% as of Sep. 15, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Medivir AB and its competitors. According to the industry distribution chart, Medivir AB ranks #582 out of 1377 companies in the Biotechnology industry, placing it in the top 42.3%.
Is Medivir AB's 3-1 Month Momentum % too high?
Medivir AB's current 3-1 Month Momentum % is N/A%. Based on the distribution chart, Medivir AB ranks #582 out of 1377 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Medivir AB has a GF Score™ of 58/100, reflecting its overall financial health beyond just this single metric.
How does Medivir AB's 3-1 Month Momentum % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Medivir AB ranks #582 out of 1377 companies for 3-1 Month Momentum %. This puts Medivir AB in the upper half of its industry. The industry median 3-1 Month Momentum % is 1.49. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
The median 3-1 Month Momentum % among Biotechnology companies is 1.49, based on 1,377 companies in the industry. Companies in the top quartile (top 25%) have a 3-1 Month Momentum % significantly above this median, while those in the bottom quartile fall well below. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Medivir AB and its competitors. For the Biotechnology industry, the median 3-1 Month Momentum % is 1.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medivir AB's current 3-1 Month Momentum % is N/A%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medivir AB stock overvalued right now?
Medivir AB (CHIX:MVIRS) has a current 3-1 Month Momentum % of N/A%. The stock's GF Value™ is kr1.34, compared to a current price of kr2.00 — trading 49% above its estimated fair value. The current 3-1 Month Momentum % is N/A%. Medivir AB's overall GF Score™ is 58/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Medivir AB (CHIX:MVIRS), the current 3-1 Month Momentum % is N/A% as of Sep. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medivir AB (CHIX:MVIRS) Overvalued in 2026?
Based on GuruFocus' analysis, Medivir AB stock appears to be overvalued.
The current stock price of kr2.00 is trading 49% above its estimated GF Value™ of kr1.34.
Key valuation signals for CHIX:MVIRS:
3-1 Month Momentum %: N/A%
GF Value™: kr1.34 vs. price of kr2.00 (49% above fair value)
No single metric tells the full story. See the CHIX:MVIRS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medivir AB develops drugs with a focus on cancer, where unmet medical needs are high. The company is concentrating on the development of fostroxacitabine bralpamide (fostrox), a liver-targeted inhibitor of DNA replication that selectively delivers the cell-killing agent to the tumor while minimizing potentially harmful effects on normal cells. It has developed two pharmaceutical products: Xerclear, used for treating labial herpes (cold sores), and Olysio, which have reached the market. Medivir also also has four out-licensed projects Xerclear, MIV-701, MBLI/MET-X. Geographically, it generates its maximum revenue from Europe and other regions.
58GF Score
Get the complete analysis for CHIX:MVIRS
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:MVIRS has been successfully added to your 
